(Q38201304)

30 August 2017

title

Omalizumab for severe asthma: efficacy beyond the atopic patient? (English)

1 reference

30 August 2017

0 references

Christian Domingo

1

1 reference

30 August 2017

publication date

1 April 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

74

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

521-533

1 reference

Phenotypic differences between pediatric and adult asthma

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

The mechanisms, diagnosis, and management of severe asthma in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Severe asthma: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Clinical characteristics and possible phenotypes of an adult severe asthma population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Recommendation for optimal management of severe refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Ultra-LAMA, ultra-LABA, ultra-inhaled steroids? The future has landed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Cluster protocols in SCIT: enough evidence for practical use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Monoclonal antibodies for chronic refractory asthma and pipeline developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Treatment strategies for allergy and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

The relevance of IgE in the pathogenesis of allergy: the effect of an anti-IgE drug in asthma and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

IgE receptors on human basophils. Relationship to serum IgE concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

IgE alone promotes human lung mast cell survival through the autocrine production of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Enhanced expression of high-affinity IgE receptor (Fc epsilon RI) alpha chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

The pharmacological basis of anti-IgE therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Omalizumab is effective in the long-term control of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Italian real-life experience of omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

The oral corticosteroid-sparing effect of omalizumab in children with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Reversibility of airway inflammation and remodelling following cessation of antigenic challenge in a model of chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Can anti-IgE therapy prevent airway remodeling in allergic asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Asthma phenotypes: the evolution from clinical to molecular approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

A qPCR-based metric of Th2 airway inflammation in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Local production of specific IgE antibodies in allergic-rhinitis patients with negative skin tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Atypical nasal challenges in patients with idiopathic rhinitis: more evidence for the existence of allergy in the absence of atopy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Localized immunoglobulin E expression in allergic rhinitis and nasal polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Impact of inadequately controlled asthma: a need for targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Efficacy of omalizumab in the treatment of nasal polyps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Mucosal tissue polyclonal IgE is functional in response to allergen and SEB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Against all odds: anti-IgE for intrinsic asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Long-term benefits of omalizumab in a patient with severe non-allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Can anti-IgE be used to treat allergy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Periostin, a novel biomarker of TH2-driven asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Diagnostic tests based on human basophils: potentials, pitfalls and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Eligibility for treatment with omalizumab in Italy and Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

Association between consistent omalizumab treatment and asthma control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

The relationship between serum IgE and surface levels of FcϵR on human leukocytes in various diseases: Correlation of expression with FcϵRI on basophils but not on monocytes or eosinophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0203-Y

The use of standardized allergen extracts. American Academy of Allergy, Asthma and Immunology (AAAAI)

21 January 2018

1 reference

12 December 2020

CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment

1 reference

12 December 2020

Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics

1 reference

12 December 2020

Effectiveness of omalizumab in non-allergic severe asthma

1 reference

12 December 2020

An update on the impact of Staphylococcus aureus enterotoxins in chronic sinusitis with nasal polyposis

1 reference

12 December 2020

In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody

1 reference

12 December 2020

Can omalizumab be effective in chronic eosinophilic pneumonia?

1 reference

12 December 2020

Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience

1 reference

12 December 2020

Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.

1 reference

12 December 2020

Sublingual immunotherapy

1 reference

12 December 2020

Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results

1 reference

12 December 2020

Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma

1 reference

12 December 2020

Unconventional treatment options in severe asthma: an overivew

1 reference

12 December 2020

'Entopy': localized mucosal allergic disease in the absence of systemic responses for atopy

1 reference

12 December 2020

Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival

1 reference

12 December 2020

Specific immunotherapy--an optimistic future

1 reference

12 December 2020

Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients

1 reference

12 December 2020

Inhibition of human IgE synthesis by anti-IgE antibodies requires divalent recognition

1 reference

12 December 2020

After 6 years with Xolair; a 3-year withdrawal follow-up

1 reference

12 December 2020

Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

1 reference

12 December 2020

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

1 reference

12 December 2020

Respirable antisense oligonucleotide (RASON) therapy for allergic asthma

1 reference

12 December 2020

Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis

1 reference

12 December 2020

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.

1 reference

12 December 2020

The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation

1 reference

12 December 2020

Twelve years' experience with methotrexate for GINA treatment step 5 asthma patients

1 reference

12 December 2020

Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study

1 reference

12 December 2020

International consensus report on diagnosis and treatment of asthma. National Heart, Lung, and Blood Institute, National Institutes of Health. Bethesda, Maryland 20892. Publication no. 92-3091, March 1992

1 reference

12 December 2020

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations

1 reference

12 December 2020

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients

1 reference

12 December 2020

Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey

1 reference

12 December 2020

Association of asthma with serum IgE levels and skin-test reactivity to allergens

1 reference

12 December 2020

Expression of the high-affinity IgE receptor on peripheral blood dendritic cells: differential binding of IgE in atopic asthma

1 reference

12 December 2020

10.1007/S40265-014-0203-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1014977970

0 references

1 reference